Innovive Reports Positive Results From Cancer Study
Posted on: Tuesday, 11 December 2007, 12:00 CST
Innovive Pharmaceuticals has reported encouraging results from a pilot study examining Inno-305, a Wilms tumor protein heteroclitic peptide immunotherapeutic vaccine, in patients with myeloid and thoracic neoplasms.
Preliminary data from the pilot study suggests repeat administration with Inno-305 is well tolerated and immune response can be elicited following three vaccinations.
In the study conducted at the Memorial Sloan-Kettering Cancer Center, patients receive six vaccinations over 12 weeks with Inno-305 along with the immune adjuvant Montanide. Preliminary data indicates that a CD4 response was seen in five of six patients and a CD8 response was seen in patients with HLA-A0201. Inno-305, also known as WT1 heteroclitic peptide immunotherapy, is unique among WT1 peptide cancer immunotherapeutics because of its ability to stimulate both CD8 and CD4 T-cells.
Steve Kelly, president and CEO of Innovive Pharmaceuticals, said: "We believe Inno-305 has the potential to elicit robust immune responses in patients with several serious cancer types including AML, CML, myelodysplastic syndrome, non small cell lung cancer and mesothelioma."
Source: Datamonitor
Related Articles
- Scientists boost cancer immune response
- Molecule That Suppresses Immune Response Under Study In Type 1 Diabetes
- Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
- Vaccine Stimulates Cancer Immune Response
- Data Indicate That Whole-Inactivated HIV-1 Immunogen Induces HIV-Specific Immune Responses in HIV-Infected, HAART-Naive Patients; Final Data From IMNR.OB's Italian Study Presented in Poster at CROI Annual Meeting
- The Immune Response Corporation Cleared to Initiate New IR103 Study in HIV Drug-Naive Patients in Italy; IR103 Clinical Program Expands to 9 Sites in 3 Countries
- Cancer Vaccine Immune Response is Studied
- The Immune Response Corporation's NeuroVax Demonstrates Increase in FOXP3 Gene Marker Levels and Treg Cell Functional Activity in MS Patients to Levels Similar to Human Controls
- The Immune Response Corporation Announces New Phase II NeuroVax Study; NeuroVax Data Support Additional Research on Promising Therapy
- AustCancer Vaccine Adjuvant Demonstrates Enhanced Immune Response in Prostate Cancer Patients
 |
 |
User Comments (0)
RSS Feeds